Get in Touch With Our Team
1300 333 420
1300 333 420
Book a Consult
Medicinal cannabis has emerged as a subject of clinical interest in recent years. Unlike recreational cannabis, medicinal varieties are specifically cultivated under controlled conditions to provide consistent cannabinoid profiles. Research indicates that cannabinoids interact with the human endocannabinoid system – a biological network involved in regulating various physiological processes, including pain sensation, mood, appetite, and immune function.
Cannabis contains numerous phytocannabinoids, with delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) being the primary compounds of scientific interest. Research suggests THC has analgesic properties along with psychoactive effects, whereas CBD has been investigated for potential anti-inflammatory and anxiolytic properties without inducing psychoactivity. Contemporary studies are examining how various cannabinoid proportions might affect clinical responses in different contexts.
When patients visit a health clinic for consultations, professionals may explain how the body's endocannabinoid network functions through a complex arrangement of naturally occurring cannabinoids, specialised receptor sites (mainly classified as CB1 and CB2),and various metabolic enzymes responsible for both creating and breaking down these endogenous compounds. CB1 receptors are predominantly found in the central nervous system, while CB2 receptors are mainly located in immune cells.This distribution may explain the diverse physiological responses observed in research settings.
Researchers have noted that the endocannabinoid system plays roles in homeostasis across multiple body systems.Ongoing studies aim to better understand how external cannabinoids may interact with this system and what implications this might have for clinical applications.
Contemporary research on medicinal cannabis extends beyond traditional administration routes. Various delivery methods being studied include:
● Oral preparations (capsules, oils, tinctures)
● Oromucosal sprays
● Vapourisation of dried flower
● Topical formulations
● Controlled-release formulations
Each method offers different pharmacokinetic profiles, bioavailability rates, and onset times, which may be relevant considerations in clinical contexts. The pharmacokinetics of these different formulations remain an active area of research.
Current scientific investigation extends to the potential interactions between multiple cannabis compounds. Beyond THC andCBD, cannabis contains numerous other cannabinoids and terpenes. Some researchers hypothesise an "entourage effect" wherein these compounds may work synergistically. This remains an area where additional research is needed to establish clinical significance.
The body of research on medicinal cannabis continues to evolve. While some preliminary studies suggest areas of potential therapeutic interest, many applications remain under investigation. Research limitations include small sample sizes, methodology variations, and the challenges of standardisation across studies.
Healthcare professionals who wish to stay informed on this topic may benefit from following developments in peer-reviewed literature and updates from regulatory bodies like the Therapeutic GoodsAdministration (TGA).
Healthcare practitioners considering medicinal cannabis as a potential option for their patients should note several important clinical considerations:
● Individual Variation: Research suggests considerable inter-individual variability in responses to cannabinoids.
● Monitoring Protocols: Regular assessment of outcomes and potential adverse effects is essential in clinical settings.
● Drug Interactions: Potential interactions with other medications should be carefully evaluated, as cannabinoids may affect the metabolism of certain drugs through cytochrome P450 pathways.
● Reported Side Effects: Commonly reported effects in studies include dry mouth, changes in appetite, temporary cognitive effects, and occasionally drowsiness.
The complexity of cannabinoid medicine underscores the importance of specialised knowledge. Healthcare providers interested in this field may benefit from additional education in cannabinoid pharmacology and clinical applications.
Comprehensive patient assessment, including thorough medical history review, medication reconciliation, and ongoing monitoring, represents the foundation of responsible clinical practice in this area.
In Australia, medicinal cannabis is regulated as a prescription-only treatment option under the oversight of the TGA.Healthcare professionals should familiarise themselves with current regulatory requirements and prescribing pathways if they wish to incorporate this treatment modality into their practice.
As scientific understanding of the endocannabinoid system and external cannabinoids continues to develop, so too does the potential for evidence-based applications. For healthcare providers interested in this evolving field, commitment to evidence-based practice, regulatory compliance, and individualised patient care remain paramount.
Triniti Health provides educational resources for healthcare professionals regarding various treatment approaches, including medicinal cannabis, within the framework of comprehensive care throughout Victoria.
Disclaimer: Triniti Health operates in accordance with the Therapeutic GoodsAdministration (TGA) regulations. The information provided in this article isfor educational purposes only and is not intended to advertise or promote theuse of any therapeutic goods, including medicinal cannabis. Always consult witha qualified healthcare professional to determine whether a particular treatmentis appropriate for your individual circumstances.
Our mission at Triniti is to provide you with advanced holistic care that prioritises forward-thinking solutions and quality of life
.jpg)
